St. Elizabeth's Medical Center of Boston Report issue

Academic/Hospital Phase 3

Organization Overview

First Clinical Trial
2005
NCT00243984
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

St Elizabeth Healthcare | St. Elizabeth Health Center | St. Elizabeth's Medical Center

Active Ingredients

Drugs in Phase 3 Trials (2)

red blood cells (1 trial)

topiramate (topamax) (1 trial)

Drugs in Other Trials (2)

platelet-rich plasma (1 trial)

urea (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Diabetes Mellitus, Type 2 (Phase 3)

Metabolic Syndrome (Phase 3)

Syndrome (Phase 3)

Weight Loss (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 4
  • # of Trial APIs: 4